Quzyttir
Payments companies reported to CMS as associated with Quzyttir. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Quzyttir, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Quzyttir
These are the largest totals companies reported as associated with Quzyttir. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Amit Mahipal | Rochester, MN | Medical Oncology | $4,605.21 |
| Maria Castells | Gardner, MA | Allergy & Immunology | $4,602.12 |
| Caitlin Zebley | Memphis, TN | Pediatric Hematology-Oncology | $4,393.84 |
| Anne Liu | Palo Alto, CA | Allergy & Immunology | $4,295.28 |
| Mazie Tsang | Scottsdale, AZ | Hematology & Oncology | $4,259.99 |
| Gladstone Mcdowell | Columbus, OH | Interventional Pain Medicine | $2,650.25 |
| Anna George | West Lake Hills, TX | Allergy & Immunology | $2,274.04 |
| Jarrod Holmes | Santa Rosa, CA | Hematology & Oncology | $1,886.50 |
| Jill Schofield | Centennial, CO | Internal Medicine | $1,270.00 |
| Robert Mittman | Bayside, NY | Allergy & Immunology | $983.42 |
Prescribed Quzyttir?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.